Profusa, Inc. entered into Amendment No. 5 to its Securities Purchase Agreement with Ascent Partners Fund LLC and completed an additional closing under the agreement on August 12, 2026. The company issued a Senior Secured Convertible Promissory Note with an aggregate principal amount of $714,285.72 for a purchase price of $650,000.00. The note bears interest at 7% per annum and is convertible into common stock at $1.07 per share, maturing on August 12, 2027. Additionally, the company entered into an Exchange Agreement to convert approximately $6.14 million in existing notes and accrued interest into Series A Non-Voting Convertible Preferred Stock at an effective conversion price of $4.28 per common share.

Profusa, Inc. reported Q2 2026 financial results and provided an update on its option agreement to acquire G3 Vision Labs. The company executed a $10.7 million Series A Convertible Exchange Agreement, converting $4.57 million into preferred stock, and borrowed $650,000 for working capital. Profusa completed a 4-for-1 reverse stock split effective August 18, 2026, to meet Nasdaq listing requirements. For the quarter ended June 30, 2026, cash on hand was $719,000 against total liabilities of $28.2 million, with a net loss of $8.8 million. The company expects G3's audited financials by mid-September and anticipates stockholders' equity to reach $28.4 million by July 31, 2026. Profusa is a digital health company developing tissue-integrated biosensors for continuous medical data transmission.

Profusa, Inc. entered into a non-binding term sheet to acquire a privately held, commercial-stage health diagnostics and toxicology testing company. The target company has estimated 2025 net revenues of approximately $111 million. The transaction is expected to create a public diagnostics company with national CLIA-certified laboratories. Consideration for the acquisition will include Profusa common stock equal to 19.99% of outstanding shares and the remainder in non-voting convertible preferred stock. Concurrently, Profusa expects to close approximately $7 million in financing via a convertible note with a 7% annual interest rate and a 9% original issue discount. Additionally, the company appointed Jack Stover as Executive Chairman and CEO, Ben Hwang as President, and Liviu Goldenberg as an independent director. Profusa is a digital health company developing tissue-integrated biosensing technologies.

Profusa, Inc. announced a 1-for-25 reverse stock split of its common stock, effective July 7, 2026, at 12:01 a.m. Eastern Time. The split will reduce the number of outstanding shares from approximately 13.2 million to approximately 530 thousand, while the authorized share count remains at 601 million. The company will pay cash in lieu of fractional shares based on the closing price on the effective date. The common stock will continue to trade on the Nasdaq Capital Market under the ticker "PFSA" with a new CUSIP number 74319X 306. The company operates in the biotechnology industry, developing biosensors and medical devices.

At a Special Meeting of Stockholders on June 23, 2026, Profusa, Inc. stockholders approved several key measures. These include authorizing the Board of Directors to execute one or more reverse stock splits between 1-for-5 and 1-for-200 through June 23, 2028. Stockholders also approved the issuance of convertible preferred stock to Bio Insights LLC for the acquisition of PanOmics Assay assets, the potential issuance of common stock exceeding 19.99% of outstanding shares upon conversion of a promissory note to NorthView Sponsor I LLC, and increasing the 2025 Equity and Incentive Plan share pool by 695,544 shares to a total of 795,930. Additionally, Lauren Chung was elected as a Class I director. The company operates in the biotechnology industry, developing sensing technologies for health monitoring.

Profusa, Inc. submitted an Advance Notice to Ascent Partners Fund LLC to purchase shares of common stock under an existing equity line of credit arrangement. The agreement includes a specific pricing mechanism involving 97% of the lowest volume-weighted average price (VWAP) over a ten-day period and a True-Up Mechanism to adjust for price fluctuations.